Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1552 Trials   75151 News 


«12...345678910111213...858859»
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Retrospective data, Review, Journal:  Long-term safety of tezepelumab in patients with asthma: a systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) -  Dec 17, 2024   
    There was no statistically significant difference in the proportion of patients with at least one adverse event (AE), AEs leading to discontinuation of study treatment, all-cause death, influenza, bronchitis, nasopharyngitis, headache, and hypertension between the two groups. Long-term (12-52 weeks) use of tezepelumab in patients with asthma does not increase the incidence of adverse events.
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen, Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis
    Journal, IO biomarker:  Adjuvant Radiation Therapy in Macroscopic Regional Nodal Melanoma. (Pubmed Central) -  Dec 17, 2024   
    Generally, ART is now used at the first recurrence. The challenge now is to find which melanomas are truly radiosensitive if ART is to have any future role in this scenario.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Retrospective data, Review, Journal:  Comprehensive Comparisons of Different Treatments for Active Graves' Orbitopathy: A Systematic Review and Bayesian Model-Based Network Meta-Analysis. (Pubmed Central) -  Dec 16, 2024   
    Teprotumumab emerges as potentially the most effective treatment for reducing inflammation and increasing overall response rates when compared to no treatment, oral mycophenolate combined with intravenous glucocorticosteroids appears to be the best one in improving proptosis. While some treatments raise safety concerns due to reported adverse events, oral methotrexate combined with intravenous glucocorticosteroids appear to offer a favorable balance between efficacy and safety among the evaluated treatments.
  • ||||||||||  Review, Journal:  Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: A state-of-the-art review. (Pubmed Central) -  Dec 16, 2024   
    Ezetimibe and bempedoic acid are reasonable options but they modestly reduce LDL-C levels (15% to 25%)...Approaches to inhibit this effect have centered on monoclonal antibodies (mAbs) (alirocumab, evolocumab) targeting PCSK9 functionality and small interfering RNA (siRNA) therapies (inclisiran) targeting the hepatic synthesis of PCSK9...Oral therapies targeting PCSK9 are, however, in development. This scoping review covers the development of current and emerging PCSK9-directed therapies, their efficacy, safety, and role in clinical practice.
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion date, Trial primary completion date:  OsteoNAFLD: Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) -  Dec 16, 2024   
    P4,  N=70, Recruiting, 
    However, studies including larger patient populations, drug dosages used, and physician perspectives on prescribing need to be studied further. Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2024 --> Sep 2025
  • ||||||||||  xaluritamig (AMG 509) / Amgen
    Enrollment open:  Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer (clinicaltrials.gov) -  Dec 16, 2024   
    P1,  N=30, Recruiting, 
    Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2024 --> Sep 2025 Not yet recruiting --> Recruiting
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  OMERIC: Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer (clinicaltrials.gov) -  Dec 16, 2024   
    P=N/A,  N=25, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Sep 2025 | Trial primary completion date: Sep 2023 --> Sep 2025
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Review, Journal, IO biomarker:  Paediatric Acute Lymphoblastic Leukaemia: A Narrative Review of Current Knowledge and Advancements. (Pubmed Central) -  Dec 14, 2024   
    For high-risk, refractory, or relapsed ALL, haematopoietic stem cell transplantation and novel therapies such as tyrosine kinase inhibitors, chimeric antigen receptor T-cell therapy, and blinatumomab immunotherapy, have improved outcomes...Continued research and clinical trials are essential to addressing the gaps treatment efficacy and prevention strategies. Efforts to improve global healthcare access and integrate novel diagnostic and therapeutic approaches are crucial for advancing outcomes for paediatric patients with ALL.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Management of Medication-Related Osteonecrosis of the Jaw: An Overview of National and International Guidelines. (Pubmed Central) -  Dec 13, 2024   
    There is disparity on strategies to reduce the risk of osteonecrosis such as the avoidance of invasive dental procedures, therapy suspension, and techniques to reduce the impact of invasive surgery. The authors recommend an international lead in the development of dental guidelines to establish a global standardised management approach aiming for better health equality.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Osteogenesis imperfecta: shifting paradigms in pathophysiology and care in children. (Pubmed Central) -  Dec 13, 2024   
    This review aims to provide insight into the pathophysiology of OI and the consequences of distinct disease-causing mutations affecting the regulation of bone homeostasis. In this context, we describe the four most recently identified OI-causing genes and provide an update on current approaches for diagnosis and treatment.
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Trial completion:  Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients (clinicaltrials.gov) -  Dec 13, 2024   
    P1/2,  N=58, Completed, 
    The higher incidence of MRONJ in patients classified as 'high risk' underscores the importance of considering individual risk factors in their treatment. Not yet recruiting --> Completed
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal, Tumor cell:  Spherical Manifolds Capture Drug-Induced Changes in Tumor Cell Cycle Behavior. (Pubmed Central) -  Dec 13, 2024   
    CDK4/6 inhibitors such as palbociclib block cell cycle progression and improve outcomes for many ER+/HER2- breast cancer patients...Understanding the molecular mechanisms that allow treated tumor cells to evade arrest is critical for identifying targets of future therapies. Ultimately, we seek to further SPCA as a tool of precision medicine, targeting treatments by individual tumors, and extending this computational framework to interpret other cyclical biological processes represented by high-dimensional data.
  • ||||||||||  Actimmune (interferon gamma-1 b) / Clinigen, Amgen
    Trial completion date, Trial primary completion date:  Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia (clinicaltrials.gov) -  Dec 13, 2024   
    P2,  N=200, Recruiting, 
    Initiation date: Oct 2024 --> Jan 2025 Trial completion date: Jun 2027 --> Jun 2026 | Trial primary completion date: Jan 2027 --> Jun 2026
  • ||||||||||  Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
    Review, Journal, Metastases:  KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies. (Pubmed Central) -  Dec 12, 2024   
    In this paper, we describe the role of KRAS mutations in NSCLC focusing on the clinical and molecular characteristics which potentially identify specific subtypes of NSCLC patients based on different KRAS mutations. We also provide an overview of the main clinical trials testing novel selective KRASG12C inhibitors as well as novel potential therapeutic strategies for NSCLC patients with non-G12C KRAS mutations.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Reduction of HLA antibodies by bi-specific antibody blinatumomab. (Pubmed Central) -  Dec 12, 2024   
    Calculated Panel Reactive Antibody (cPRA), a measurement of the possibility of getting immunologically compatible donors, was also lowered after blinatumomab infusion. Our observation suggests that blinatumomab can be a potential drug for desensitization therapy.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Treating Osteoporosis in Patients with Atypical Femoral Fracture. (Pubmed Central) -  Dec 12, 2024   
    Patients who have suffered an atypical femoral fracture while on bisphosphonates or denosumab may continue to be at risk for typical osteoporotic fractures...One potential (but not FDA-approved) method is to use long-term cyclic teriparatide or abaloparatide on a three-months on, three-months off schedule. Tailoring the approach to each patient is important, based on the five clinical principles, in the absence of evidence-based management recommendations.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Retrospective data, Journal, IO biomarker:  Philadelphia-like B-cell acute lymphoblastic Leukaemia: Disease features and outcomes in the era of immunotherapy. (Pubmed Central) -  Dec 12, 2024   
    However, patients who received blinatumomab within 1-year pre-HSCT had improved DFS (HR?=?0.43; 95% CI 0.20-0.94; p?=?0.034) and CIR (HR?=?0.26; 95% CI 0.09-0.75; p?=?0.13). In conclusion, our data suggest that Ph-like is less likely to respond to standard induction therapy and HSCT may result in similar survival outcomes to Ph-negative ALL.